Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Heart Failure With Preserved Ejection Fraction (HFPEF): full-pipeline trial registry
8 of 10 indexed Heart Failure With Preserved Ejection Fraction (HFPEF) trials are currently recruiting.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 8 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Heart Failure With Preserved Ejection Fraction (HFPEF): 10 US clinical trials tracked, 8 recruiting.
Heart Failure With Preserved Ejection Fraction (HFPEF) is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Occlutech International AB, running 1 of these trials.
Enrollment posture brief
Registry condition heart-failure-with-preserved-ejection-fraction-hfpef
OPEN 8 | RECR 80% | LATE 2 | EARLY 2 | RANK #1724 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Ablation (80% recruiting · 5 trials)
Heart Failure With Preserved Ejection Fraction (HFPEF) lists 8 open slots (80% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Heart Failure With Preserved Ejection Fraction (HFPEF) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Heart Failure With Preserved Ejection Fraction (HFPEF) is recruiting above its size-band peers.
8 of 10 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Heart Failure With Preserved Ejection Fraction (HFPEF) trials is spread across many organizations.
Occlutech International AB accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical Heart Failure With Preserved Ejection Fraction (HFPEF) enrolment sits around 150 participants.
Median target enrolment is 150 among the 10 trials that report a genuine target (sentinel values excluded). 4 of those (40%) plan for fewer than 100 participants.
-
Heart Failure With Preserved Ejection Fraction (HFPEF) research is mostly interventional.
7 interventional and 3 observational studies make up this index (70% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
ELEVATE-HFpEF Clinical Study
Medtronic Cardiac Rhythm and Heart Failure
NCT06678841
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
Syed Hamza Mufarrih
NCT07053475
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
Cedars-Sinai Medical Center
NCT03876223
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
Axon Therapies
NCT04592445
The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
University of Texas Southwestern Medical Center
NCT06930495
The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
University of Mississippi Medical Center
NCT07052539
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Vasa Therapeutics
NCT07219511
Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Secretome Therapeutics
NCT06560762
Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study
Occlutech International AB
NCT05136820
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
Novartis Pharmaceuticals
NCT03988634
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Heart Failure With Preserved Ejection Fraction (HFPEF) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Heart Failure With Preserved Ejection Fraction (HFPEF) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Heart Failure With Preserved Ejection Fraction (HFPEF) page
10 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Heart Failure With Preserved Ejection Fraction (HFPEF) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Occlutech International AB sponsors the most Heart Failure With Preserved Ejection Fraction (HFPEF) trials on record, review their full trial history before evaluating a specific study. See Occlutech International AB's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Heart Failure With Preserved Ejection Fraction (HFPEF) condition card totals 10 registered trials; most-linked intervention valsartan matching placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.